Safety of SSRI Use During Pregnancy

General Safety Assessment

SSRIs may be continued during pregnancy when clinically indicated because the absolute risks of adverse maternal‑fetal outcomes are generally small and must be weighed against the substantial risks of untreated maternal depression, which include preterm birth and maternal morbidity. 1

Most selective serotonin reuptake inhibitors do not significantly increase the risk of major congenital malformations when analyses properly adjust for maternal psychiatric illness. 1
Paroxetine warrants special caution: it was classified by the FDA as pregnancy category D in 2005 due to concerns about cardiac malformations, yet recent large‑scale cohort data (≈ 1 million pregnancies) have not demonstrated a definitive link between first‑trimester antidepressant exposure and cardiac defects. 1

Antidepressant exposure in pregnancy is associated with a small absolute increase in several obstetric risks compared with untreated depression. 1
Preterm delivery: SSRI use may raise the risk of preterm birth relative to untreated depression, although the absolute increase remains modest. 1
Persistent pulmonary hypertension of the newborn (PPHN): Evidence is conflicting; a meta‑analysis estimates a number‑needed‑to‑harm of 286–351 for late‑pregnancy SSRI exposure, indicating a low absolute risk. 1

Exposure to SSRIs in the third trimester can produce a transient neonatal adaptation syndrome characterized by continuous crying, irritability, jitteriness, tremors, increased muscle tone, rapid breathing, feeding difficulties, sleep disturbance, and, rarely, hypoglycemia or seizures. 2
Symptoms typically begin within hours to several days after birth and resolve within 1–2 weeks (occasionally up to 4 weeks). 2
The clinical picture reflects either a mild serotonin‑syndrome–like state or SSRI withdrawal, both of which are generally self‑limited. 2

Current evidence provides reassurance that prenatal SSRI exposure does not cause long‑term neurodevelopmental harm; observed associations with autism spectrum disorder and attention‑deficit/hyperactivity disorder are largely attributable to confounding by maternal psychiatric illness rather than a causal drug effect. 3
The consensus across multiple study designs (cohort, case‑control, sibling‑comparison) supports the interpretation that SSRI exposure is not an independent risk factor for these neurodevelopmental disorders. 3

Assess depression severity: Untreated maternal depression carries significant risks, including premature birth, reduced breastfeeding initiation, and increased maternal morbidity. 1
Medication selection: Avoid paroxetine when possible because of historic FDA concerns, although newer data are more reassuring; sertraline (and, if needed, paroxetine) are preferred during breastfeeding due to minimal transfer into breast milk. 1
Timing considerations: For SSRI use after 20 weeks’ gestation, counsel patients about the small absolute risk of PPHN (NNH ≈ 286–351). 1

Do not assume that all observed associations between SSRI use and adverse outcomes are causal; most are confounded by underlying maternal psychiatric illness and related risk factors. 3
Do not overlook the risks of untreated depression, which is linked to premature birth and decreased breastfeeding rates. 1

Sertraline exposure through breast milk is minimal, delivering <10 % of the maternal daily dose to the infant (weight‑adjusted) and yielding infant‑to‑maternal plasma concentration ratios uniformly < 0.10; no infant complications have been linked, supporting continuation of sertraline during breastfeeding. American Academy of Pediatrics 4
Paroxetine also shows a favorable breast‑milk profile, with infant‑to‑maternal plasma ratios uniformly < 0.10, making it acceptable for lactation when the mother is already established on the drug. American Academy of Pediatrics 4

FDA pregnancy‑category D classification (2005) for paroxetine was based on concerns about congenital cardiac malformations. U.S. Food and Drug Administration 5
Large population‑based cohort (≈ 1 million pregnancies) found no definitive association between first‑trimester paroxetine use and cardiac malformations. American Family Physician 5
Neonatal withdrawal/adaptation signs after in‑utero paroxetine exposure may persist up to 4 weeks, longer than for other SSRIs. American Academy of Pediatrics [6][7]

Transient neonatal adaptation syndrome can follow third‑trimester SSRI exposure, presenting with continuous crying, irritability, jitteriness, tremors, hypertonia, tachypnea, feeding difficulty, sleep disturbance, and rarely hypoglycemia or seizures. Onset occurs within hours to several days after birth and typically resolves within 1–2 weeks (occasionally up to 4 weeks). American Academy of Pediatrics 6
Clinical monitoring: Early post‑discharge follow‑up is recommended to observe for adaptation syndrome; symptoms usually resolve without intervention. American Academy of Pediatrics 6

Prenatal SSRI exposure has not been shown to cause long‑term neurodevelopmental harm; recent reviews found no adverse outcomes in children exposed in utero. American Academy of Pediatrics 6

Untreated maternal depression is associated with adverse maternal and fetal outcomes, including premature birth, reduced initiation of breastfeeding, and increased maternal morbidity. American Family Physician 5

Late‑pregnancy SSRI exposure carries a small absolute risk of PPHN, with an estimated number‑needed‑to‑harm of 286–351. American Family Physician 5

Standard SSRI doses during pregnancy are not linked to adverse perinatal outcomes, supporting the use of the lowest effective dose throughout gestation. American Academy of Pediatrics 6